Evidence map›Paper›PMID 31471158›Full record

ArticleThe Lancet. Oncology2019

Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study.

Andrew C Dietz, Kristy Seidel, Wendy M Leisenring, Daniel A Mulrooney, Jean M Tersak, Richard D Glick, Cathy A Burnweit, Daniel M Green, Lisa R Diller, Susan A Smith and 6 more

Abstract read
In one paragraph

Article in The Lancet. Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Kidney disease and transplantation in childhood cancer survivors.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  4. Article
  5. Harnessing the evolving CRISPR/Cas9 for precision oncology.Journal of translational medicine · 2024
    Review
  6. Article
  7. Article
  8. Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  9. Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

Andrew C DietzChildren's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA; bluebird bio, Cambridge, MA, USA.
Kristy SeidelFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Wendy M LeisenringFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Daniel A MulrooneySt Jude Children's Research Hospital, Memphis, TN, USA.
Jean M TersakChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA.
Richard D GlickCohen Children's Medical Center, Hofstra Northwell School of Medicine, New Hyde Park, NY, USA.
Cathy A BurnweitNicklaus Children's Hospital, Miami, FL, USA.
Daniel M GreenSt Jude Children's Research Hospital, Memphis, TN, USA.
Lisa R DillerDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Susan A SmithThe University of Texas at MD Anderson Cancer Center, Houston, TX, USA.
Rebecca M HowellThe University of Texas at MD Anderson Cancer Center, Houston, TX, USA.
Marilyn StovallThe University of Texas at MD Anderson Cancer Center, Houston, TX, USA.
Gregory T ArmstrongSt Jude Children's Research Hospital, Memphis, TN, USA.
Kevin C OeffingerDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Leslie L RobisonSt Jude Children's Research Hospital, Memphis, TN, USA.
Amanda M TermuhlenChildren's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA; Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA. Electronic address: atermuhl@umn.edu.
St. Jude Children's Research Hospital · USThe University of Texas MD Anderson Cancer Center · USFred Hutch Cancer Center · USChildren's Hospital of Los Angeles · USChildren's Hospital of Pittsburgh · USCohen Children's Medical Center · USDuke University · USHarvard University · USMiami Children's Hospital · USUniversity of Minnesota Medical Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Mach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA021765NCI NIH HHS U24 CA055727
6 · The paper itself

Abstract

backgroundSerious chronic medical conditions occur in childhood cancer survivors. We aimed to investigate incidence of and risk factors for end-organ damage resulting in registration on a waiting list for or receiving a solid organ transplantation and 5-year survival following these procedures.

methodsThe Childhood Cancer Survivor Study (CCSS) is a retrospective cohort of individuals who survived at least 5 years after childhood cancer diagnosed at younger than 21 years of age, between Jan 1, 1970, and Dec 31, 1986, at one of 25 institutions in the USA. We linked data from CCSS participants treated in the USA diagnosed between Jan 1, 1970, and Dec 31, 1986 (without solid organ transplantation before cohort entry) to the Organ Procurement and Transplantation Network-a database of all US organ transplants. Eligible participants had been diagnosed with leukaemia, lymphoma, malignant CNS tumours, neuroblastoma, Wilms' tumours, and bone and soft tissue sarcomas. The two primary endpoints for each type of organ transplant were date of first registration of a transplant candidate on the waiting list for an organ and the date of the first transplant received. We also calculated the cumulative incidence of being placed on a waiting list or receiving a solid organ transplantation, hazard ratios (HRs) for identified risk factors, and 5-year survival following transplantation.

findingsOf 13 318 eligible survivors, 100 had 103 solid organ transplantations (50 kidney, 37 heart, nine liver, seven lung) and 67 were registered on a waiting list without receiving a transplant (21 kidney, 25 heart, 15 liver, six lung). At 35 years after cancer diagnosis, the cumulative incidence of transplantation or being on a waiting list was 0·54% (95% CI 0·40-0·67) for kidney transplantation, 0·49% (0·36-0·62) for heart, 0·19% (0·10-0·27) for liver, and 0·10% (0·04-0·16) for lung. Risk factors for kidney transplantation were unilateral nephrectomy (HR 4·2, 95% CI 2·3-7·7), ifosfamide (24·9, 7·4-83·5), total body irradiation (6·9, 2·3-21·1), and mean kidney radiation of greater than 15 Gy (>15-20 Gy, 3·6 [1·5-8·5]; >20 Gy 4·6 [1·1-19·6]); for heart transplantation, anthracycline and mean heart radiation of greater than 20 Gy (dose-dependent, both p<0·0001); for liver transplantation, dactinomycin (3·8, 1·3-11·3) and methotrexate (3·3, 1·0-10·2); for lung transplantation, carmustine (12·3, 3·1-48·9) and mean lung radiation of greater than 10 Gy (15·6, 2·6-92·7). 5-year overall survival after solid organ transplantation was 93·5% (95% CI 81·0-97·9) for kidney transplantation, 80·6% (63·6-90·3) for heart, 27·8% (4·4-59·1) for liver, and 34·3% (4·8-68·6) for lung.

interpretationSolid organ transplantation is uncommon in ageing childhood cancer survivors. Organ-specific exposures were associated with increased solid organ transplantation incidence. Survival outcomes showed that solid organ transplantation should be considered for 5-year childhood cancer survivors with severe end-organ failure.

fundingUS National Institute of Health, American Lebanese Syrian Associated Charities, US Health Resources and Services Administration.

Indexed as

AdolescentAdultCancer SurvivorsChildChild, PreschoolEnd Stage Liver DiseaseFemaleHeart FailureHeart TransplantationHumansIncidenceInfantInfant, NewbornKidney Failure, ChronicKidney TransplantationLiver Transplantation

Identifiers

PMID31471158
PMCPMC6871649
OpenAlexW2970450032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.